Molecular Devices expands access to automated, AI-ready research solutions through partnership with Automata’s LINQ platform
10 Feb 2026
Molecular Devices has announced a new collaboration with Automata, the London‑based lab automation company developing fully integrated, AI‑ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices’ imaging and detection systems and Automata’s LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.
Molecular Devices has a long history of designing instruments for automated environments, from the ImageXpress HCS.ai High-Content Screening System optimized for handsfree acquisition to SpectraMax Multi-Mode Microplate Readers that integrate seamlessly with robotics and scheduling tools. Now integrated into Automata’s LINQ platform — which unifies instruments, robotics, and software — these systems support the generation of high-quality datasets for AI-powered discovery.
“Many of today’s scientific teams are working to increase productivity and data quality without adding operational complexity,” said Lars Hartvig Kristiansen, Vice President, Product Innovation and Strategy, Molecular Devices. “Combining Molecular Devices’ microplate readers and high-content screening systems with Automata’s LINQ platform gives customers a clear path to connected, scalable workflows.”
The collaboration includes Danaher Ventures’ participation in Automata’s Series C round and board appointment, alongside expanded automation options enabled by Beckman Coulter Life Sciences instrument integration.
